Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 1.00 |
| ▸ | CTSL | P07711 | 18/20 | 1.00 |
| ▸ | CTSS | P25774 | 14/20 | 1.00 |
| ▸ | CTSB | P07858 | 4/20 | 1.00 |
| ▸ | CTSV | O60911 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Relacatib SCHEMBL30218824 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL29394783 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL27107043 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL30218825 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL6215260 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL23856125 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL6841517 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| Relacatib SCHEMBL7258401 | 1.00 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6842090 | 0.92 | CTSK (0.86) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL13784216 | 0.91 | CTSK (0.84) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| US-20100331545-A1 | REGULATOR FOR SIGNALING TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-12-30 | — | — | US | claimed |
| EP-2216047-A1 | REGULATOR FOR SIGNALING OF TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | National University Corporation Tokyo Medical and Dental University (JP) | 2010-08-11 | — | — | EP | claimed |
| EP-2168600-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | Nippon Chemiphar Co., Ltd. (JP) | 2010-03-31 | — | — | EP | claimed |
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| EP-4204020-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Advanced Accelerator Applications International S.A. (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-4204021-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Advanced Accelerator Applications International S.A. (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-4125919-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | disclosed |
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | disclosed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | CTSK 1017/4885CTSL 699/4885CTSS 1482/4885 |
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | ACMSD, CPS1, BCAT2 | CTSK 2482/4885CTSL 2386/4885CTSS 1620/4885 |
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | CTSV, CTSS, CTSA | CTSK 11/4885CTSL 10/4885CTSS 2/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSL 11/4885CTSS 5/4885 |
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | SERPINB1, ECE1, MME | CTSK 141/4885CTSL 155/4885CTSS 37/4885 |
| US-20100331545-A1 | REGULATOR FOR SIGNALING TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | TLR1, TLR7, TLR6 | CTSK 19/4885CTSL 22/4885CTSS 7/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | CTSK 1049/4885CTSL 608/4885CTSS 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.